





Figure 1






Figure 3

4/23




Figure 4

5/23




Figure 5

B16-F10 Melanoma Bilateral Tumor Implantation model




Figure 6

7/23




Figure 7

8/23




Figure 7

9/23




Figure 7

10/23




Figure 7

11/23




Figure 8

12/23




Figure 8




Figure 8

14/23




Figure 8

15/23




Figure 9




Figure 10




Figure 10




Figure 10

Gating strategy to separate CD103⁺ and CD11b⁺ DCs




Figure 11




Figure 12

Bilateral 4T1
breast cancer model




Figure 13

22/23

Unilateral established
large B16-F10 melanoma




Figure 14




Figure 14